Visen Set to Start Phase 3 Trial of TransCon PTH in China

Visen Set to Start Phase 3 Trial of TransCon PTH in China

296620

Visen Set to Start Phase 3 Trial of TransCon PTH in China

Visen Pharmaceuticals has obtained regulatory clearance to start the PaTHway China Trial, a Phase 3 study of TransCon PTH as a hormone replacement therapy for people with hypoparathyroidism in China. The approval from China’s Center for Drug Evaluation of the National Medical Products Administration came on June 1, which also marks World Hypopara Awareness Day every year. “It is very encouraging to obtain the [investigational new drug] approval for [the] Phase III clinical trial in…

You must be logged in to read/download the full post.